21.96
price down icon3.30%   -0.75
after-market アフターアワーズ: 21.94 -0.02 -0.09%
loading
前日終値:
$22.71
開ける:
$22.745
24時間の取引高:
286.29K
Relative Volume:
0.46
時価総額:
$1.62B
収益:
$81.26M
当期純損益:
$-102.66M
株価収益率:
-16.05
EPS:
-1.3678
ネットキャッシュフロー:
$-77.62M
1週間 パフォーマンス:
-3.94%
1か月 パフォーマンス:
-15.99%
6か月 パフォーマンス:
-2.53%
1年 パフォーマンス:
+74.84%
1日の値動き範囲:
Value
$21.80
$22.75
1週間の範囲:
Value
$21.80
$23.59
52週間の値動き範囲:
Value
$11.51
$29.75

Zymeworks Inc. Stock (ZYME) Company Profile

Name
名前
Zymeworks Inc.
Name
セクター
Healthcare (1079)
Name
電話
604-678-1388
Name
住所
1385 West 8th Avenue, Suite 540, Vancouver, BC
Name
職員
170
Name
Twitter
@ZymeworksInc
Name
次回の収益日
2026-08-06
Name
最新のSEC提出書
Name
ZYME's Discussions on Twitter

Compare ZYME vs VRTX, REGN, ARGX, RVMD, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
ZYME icon
ZYME
Zymeworks Inc.
21.96 1.69B 81.26M -102.66M -77.62M -1.3678
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
477.10 121.57B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
762.63 69.95B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
853.82 55.61B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
187.53 39.98B 742.00K -1.37B -1.07B -7.0731
ONC icon
ONC
Beone Medicines Ltd Adr
316.01 33.81B 5.76B 514.49M 1.10B 4.4813

Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-12-12 アップグレード Wells Fargo Equal Weight → Overweight
2025-12-03 開始されました Citizens JMP Mkt Outperform
2025-10-24 再開されました Wells Fargo Equal Weight
2025-10-14 アップグレード H.C. Wainwright Neutral → Buy
2025-10-10 開始されました B. Riley Securities Buy
2025-05-20 開始されました TD Cowen Buy
2024-12-16 アップグレード JP Morgan Neutral → Overweight
2024-11-07 アップグレード Leerink Partners Market Perform → Outperform
2024-11-01 ダウングレード Wells Fargo Overweight → Equal Weight
2023-03-21 再開されました Wells Fargo Overweight
2023-01-04 繰り返されました H.C. Wainwright Neutral
2022-12-20 アップグレード Jefferies Hold → Buy
2022-11-01 ダウングレード H.C. Wainwright Buy → Neutral
2022-10-21 ダウングレード SVB Leerink Outperform → Mkt Perform
2022-10-04 再開されました Wells Fargo Overweight
2022-05-05 アップグレード Guggenheim Neutral → Buy
2022-03-15 開始されました Evercore ISI Outperform
2021-12-10 アップグレード SVB Leerink Mkt Perform → Outperform
2021-11-17 再開されました Guggenheim Neutral
2021-10-07 開始されました Jefferies Hold
2021-03-31 開始されました Credit Suisse Outperform
2021-02-25 ダウングレード SVB Leerink Outperform → Mkt Perform
2021-02-08 再開されました H.C. Wainwright Buy
2021-01-25 ダウングレード Citigroup Buy → Neutral
2020-09-29 再開されました JP Morgan Neutral
2020-08-06 開始されました SVB Leerink Outperform
2020-01-10 開始されました Wolfe Research Outperform
2019-12-09 開始されました JP Morgan Neutral
2019-11-25 開始されました H.C. Wainwright Buy
2019-11-20 開始されました Guggenheim Buy
2019-09-30 アップグレード Raymond James Outperform → Strong Buy
2019-08-30 開始されました Stifel Buy
2019-07-18 開始されました Deutsche Bank Buy
2018-05-11 アップグレード Barclays Underweight → Equal Weight
2018-03-19 開始されました Raymond James Outperform
すべてを表示

Zymeworks Inc. (ZYME) 最新ニュース

pulisher
Jul 28, 2026

Rubric Capital Management LP Acquires 1,250,000 Shares of Zymeworks Inc. $ZYME - MarketBeat

Jul 28, 2026
pulisher
Jul 28, 2026

Zymeworks Inc (ZYME) Valuation: PE, PB & Fair Value Analysis - TradingKey

Jul 28, 2026
pulisher
Jul 27, 2026

Zymeworks Inc (ZYME) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

Zymeworks Inc (ZYME) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

SummitTX Capital L.P. Purchases 97,159 Shares of Zymeworks Inc. $ZYME - MarketBeat

Jul 27, 2026
pulisher
Jul 27, 2026

Zymeworks Inc (ZYME) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

Zymeworks Inc (ZYME) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

Zymeworks Inc (ZYME) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Jul 27, 2026
pulisher
Jul 26, 2026

Zymeworks Inc (ZYME) Balance Sheet - TradingKey

Jul 26, 2026
pulisher
Jul 26, 2026

TradingKey - TradingKey

Jul 26, 2026
pulisher
Jul 25, 2026

Zymeworks Inc. Revenue Breakdown – LSX:A3DSSN - TradingView

Jul 25, 2026
pulisher
Jul 24, 2026

Zymeworks Inc. (ZYME) Stock Analysis: A 70% Upside Potential Amidst Biotech Innovations - DirectorsTalk Interviews

Jul 24, 2026
pulisher
Jul 24, 2026

ZYME|Zymeworks Inc|Price:22.860|Chg%:-0.260 - TradingKey

Jul 24, 2026
pulisher
Jul 17, 2026

Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026 - Sahm

Jul 17, 2026
pulisher
Jul 16, 2026

Zymeworks to report Q2 2026 financial results on August 6 - scanx.trade

Jul 16, 2026
pulisher
Jul 16, 2026

Zymeworks Inc. to Announce Second Quarter 2026 Financial Results on August 6, 2026 - Quiver Quantitative

Jul 16, 2026
pulisher
Jul 16, 2026

Zymeworks Won’t Host Q2 Call Amid Proposed Theravance Deal - Stock Titan

Jul 16, 2026
pulisher
Jul 15, 2026

Truist Remains Bullish on Zymeworks (ZYME) – Here’s Why - Yahoo Finance

Jul 15, 2026
pulisher
Jul 14, 2026

ETFs Investing in Zymeworks Inc. Stocks - TradingView

Jul 14, 2026
pulisher
Jul 14, 2026

Hillsdale Investment Management Inc. Has $8.65 Million Stock Position in Zymeworks Inc. $ZYME - MarketBeat

Jul 14, 2026
pulisher
Jul 13, 2026

Pictet Asset Management Holding SA Has $232,000 Stock Position in Zymeworks Inc. $ZYME - MarketBeat

Jul 13, 2026
pulisher
Jul 08, 2026

Theravance stock down 3% after Zymeworks announces buyout - MSN

Jul 08, 2026
pulisher
Jul 07, 2026

Zymeworks ZW49 from ZYMEantibody drug conjugate targets solid tumors - Ad-hoc-news.de

Jul 07, 2026
pulisher
Jul 07, 2026

Zymeworks Inc outlines its biotech strategy as investors track clinical progress - ad-hoc-news.de

Jul 07, 2026
pulisher
Jul 07, 2026

Zymeworks: A Deep Dive (NASDAQ:ZYME) - Seeking Alpha

Jul 07, 2026
pulisher
Jul 06, 2026

Form 4 Zymeworks Inc For: 6 July By Investing.com - Investing.com Nigeria

Jul 06, 2026
pulisher
Jul 06, 2026

Zymeworks (ZYME) COO acquires 939 ESPP shares at discounted $22.22 - Stock Titan

Jul 06, 2026
pulisher
Jul 06, 2026

Price to book forward of Zymeworks Inc. – NASDAQ:ZYME - TradingView

Jul 06, 2026
pulisher
Jul 05, 2026

Zymeworks' $929 Million Pivot: How a COPD Acquisition Redefines Its Future - Kavout | AI

Jul 05, 2026
pulisher
Jul 05, 2026

Zymeworks Q1 2026 presentation: zanidatamab nears FDA decision - Investing.com

Jul 05, 2026
pulisher
Jul 05, 2026

Zymeworks (ZYME) Breaks Out: +2.29% Rally Tests Key Resistance Near $27.63Buffered ETF - dars.gov.et

Jul 05, 2026
pulisher
Jul 03, 2026

Enterprise value to EBIT forward of Zymeworks Inc. – NASDAQ:ZYME - TradingView

Jul 03, 2026
pulisher
Jul 03, 2026

Zymeworks Inc outlines its antibody-drug conjugate strategy as investors watch oncology partnerships - Ad-hoc-news.de

Jul 03, 2026
pulisher
Jul 01, 2026

Zymeworks Inc. (ZYME): Exploring the Potential of an Undervalued Biotech in OncologyEarnings Stability Report - dars.gov.et

Jul 01, 2026
pulisher
Jul 01, 2026

ZYME Q1 2026 Earnings: Wide EPS Miss Amid No Revenue as Operating Losses DeepenReturn On Assets - dars.gov.et

Jul 01, 2026
pulisher
Jul 01, 2026

Here’s Why Zymeworks Inc. Paid $929M For Theravance Biopharma (NASDAQ:ZYME) - Seeking Alpha

Jul 01, 2026
pulisher
Jul 01, 2026

Zymeworks (ZYME) Stock Looks Fully Valued Despite Its 205% Three Year Run - Yahoo Finance

Jul 01, 2026
pulisher
Jul 01, 2026

Arthur Cox advises Theravance Biopharma on its $929 million merger with Zymeworks - Arthur Cox LLP

Jul 01, 2026
pulisher
Jul 01, 2026

Enterprise value to revenue forward of Zymeworks Inc. – BOATS:ZYME - TradingView

Jul 01, 2026
pulisher
Jul 01, 2026

The Zymeworks ZW25 bispecific antibodya flexible HER2 therapy option for oncology partners - ad-hoc-news.de

Jul 01, 2026
pulisher
Jun 30, 2026

Canadian Zymeworks acquires American Theravance Biopharma for $929 million - AKM.RU

Jun 30, 2026
pulisher
Jun 30, 2026

Is Zymeworks Inc. (ZYME) Stock an Undervalued Biotech Opportunity With Oncology Growth Ahead? - Insider Monkey

Jun 30, 2026
pulisher
Jun 30, 2026

After a three-decade legacy, Theravance agreed to a complex sale for less than $1 billion - The Business Journals

Jun 30, 2026
pulisher
Jun 30, 2026

Zymeworks Inc. (ZYME) M&A CallSlideshow (NASDAQ:ZYME) 2026-06-30 - Seeking Alpha

Jun 30, 2026
pulisher
Jun 30, 2026

Theravance Stock Down 3% After Zymeworks Announces Buyout - Yahoo Finance

Jun 30, 2026
pulisher
Jun 30, 2026

Press Release: Zymeworks to Acquire Theravance Biopharma, Inc. - Moomoo

Jun 30, 2026
pulisher
Jun 30, 2026

Zymeworks agrees to buy Theravance Biopharma for $929m - Pharmaceutical Technology

Jun 30, 2026
pulisher
Jun 29, 2026

Zymeworks to buy troubled U.S.-Irish pharma company Theravance for US$929M - The Logic

Jun 29, 2026
pulisher
Jun 29, 2026

Vancouver biotech Zymeworks buying Theravance for US$929M - Castanet

Jun 29, 2026
pulisher
Jun 29, 2026

Zymeworks Inc to Acquire Theravance Biopharma Inc Transcript - GuruFocus

Jun 29, 2026
pulisher
Jun 29, 2026

Zymeworks Inc. Stock 12‑Month Price Target Raised to $38.75, Implies 60% Upside - TradingView

Jun 29, 2026

Zymeworks Inc. (ZYME) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$90.58
price down icon 2.44%
$119.52
price down icon 2.82%
$33.91
price down icon 1.77%
$58.43
price down icon 1.00%
$205.52
price up icon 0.02%
ONC ONC
$316.01
price down icon 1.88%
大文字化:     |  ボリューム (24 時間):